Vaccinogen Inc. entered into an agreement with Dublin City University, through one of its subsidiaries, to provide an exclusive two-year option to evaluate and acquire a high-throughput, multiplex, analysis platform, DiCAST.
CVS Health marked the first anniversary of ending tobacco sales at its CVS/pharmacy locations, and released study data showing a reduction in cigarette purchases over the past year.
Sequenom Inc. entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center to explore the utility of Sequenom's new liquid biopsy assay to comprehensively profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients.
Janssen Biotech Inc. announced an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in phase I clinical studies.
TROVAGENE INC. established the Trovagene Research Institute, a European subsidiary focused on expanding the capabilities and adoption of the company's Precision Cancer Monitoring platform. Trovagene has also entered into a collaboration with the Department of Oncology at the University of Torino.
HERBERT FRITSCHE received the 2015 Abbott Award from the International Society of Oncology and Biomarkers for contributions to the field of basic or clinical oncology.
CARLOS ARTEAGA and FREDERICK ALT were named the winners of the 2015 Prize for Scientific Excellence by the American-Italian Cancer Foundation.
The 70th annual Lasker Awards went to: Evelyn Witkin and Stephen Elledge for basic medical research; James Allison for clinical research; and Doctors Without Borders for public service.
The U.S. Government Accountability Office said it would investigate the controversy stemming from wide use of power morcellators, gynecological devices now known to spread undetected cancers during hysterectomies and myomectomies.
The Health Resources and Services Administration issued the long-awaited “mega-rule” intended to define who qualifies for deep discounts on drug prices under the federal 340B program.
